AGA Clinical Practice Guideline on Fecal Microbiota–Based Therapies for Select Gastrointestinal Diseases

Gastroenterology, Journal Year: 2024, Volume and Issue: 166(3), P. 409 - 434

Published: Feb. 21, 2024

Fecal microbiota-based therapies include conventional fecal microbiota transplant and US Food Drug Administration-approved therapies, live-jslm spores live-brpk. The American Gastroenterological Association (AGA) developed this guideline to provide recommendations on the use of in adults with recurrent Clostridioides difficile infection; severe fulminant C inflammatory bowel diseases, including pouchitis; irritable syndrome.

Language: Английский

---

Fecal microbiota transplantation: current challenges and future landscapes

Clinical Microbiology Reviews, Journal Year: 2024, Volume and Issue: 37(2)

Published: May 8, 2024

SUMMARYGiven the importance of gut microbial homeostasis in maintaining health, there has been considerable interest developing innovative therapeutic strategies for restoring microbiota. One such approach, fecal microbiota transplantation (FMT), is main "whole microbiome replacement" strategy and integrated into clinical practice guidelines treating recurrent

Language: Английский

---

A systematic framework for understanding the microbiome in human health and disease: from basic principles to clinical translation

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: Sept. 23, 2024

Language: Английский

---

Protective effects of fecal microbiota transplantation against ischemic stroke and other neurological disorders: an update

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Feb. 21, 2024

The bidirectional communication between the gut and brain or gut-brain axis is regulated by several microbes microbial derived metabolites, such as short-chain fatty acids, trimethylamine N-oxide, lipopolysaccharides. Gut microbiota (GM) produce neuroactives, specifically neurotransmitters that modulates local central neuronal functions. An imbalance intestinal commensals pathobionts leads to a disruption in dysbiosis, which affects barrier integrity gut-immune neuroimmune systems. Currently, fecal transplantation (FMT) recommended for treatment of recurrent

Language: Английский

---

Fecal microbiota transplantation alters gut phage communities in a clinical trial for obesity

Microbiome, Journal Year: 2024, Volume and Issue: 12(1)

Published: July 6, 2024

Abstract Background Fecal microbiota transplantation (FMT) is a therapeutic intervention used to treat diseases associated with the gut microbiome. In human microbiome, phages have been implicated in influencing health, successful engraftment of donor correlated FMT treatment efficacy. The impact that gastrointestinal exert on health has primarily connected their ability modulate bacterial communities gut. Nonetheless, how affects recipients’ phage populations, and turn, this influences environment, not yet fully understood. study, we investigated effects phageome composition participants within Gut Bugs Trial (GBT), double-blind, randomized, placebo-controlled trial efficacy treating obesity comorbidities adolescents. Stool samples collected from donors at time recipients four points (i.e., baseline 6 weeks, 12 26 weeks post-intervention), underwent shotgun metagenomic sequencing. Phage sequences were identified characterized silico examine evidence assess extent FMT-induced alterations composition. Results Donor engrafted stably following FMT, composing significant proportion for entire course study (33.8 ± 1.2% females 33.9 3.7% males). varied between was positively alpha diversity. caused shift toward donors’ increased diversity variability over time. Conclusions significantly altered recipients' and, overall, microbial populations. increase consistent population dynamics. This proposes play critical role modulating environment suggests novel approaches understanding altering recipient’s registration registered Australian New Zealand Clinical Trials Registry (ACTR N12615001351505). protocol: protocol available https://bmjopen.bmj.com/content/9/4/e026174 .

Language: Английский

---

The role of the microbiome in liver disease

Current Opinion in Gastroenterology, Journal Year: 2024, Volume and Issue: 40(3), P. 134 - 142

Published: Feb. 16, 2024

Purpose of review The intestinal microbiome and the gut-liver axis play a major role in health disease. human gut harbors trillions microbes disruption homeostasis can contribute to liver In this review, progress field within last 3 years is summarized, focusing on metabolic dysfunction-associated steatotic disease (MASLD), alcohol-associated (ALD), autoimmune (AILD), hepatocellular carcinoma (HCC). Recent findings Changes fecal virome fungal mycobiome have been described patients with various diseases. Several microbial derived metabolites including endogenous ethanol produced by bacteria, mechanistically linked such as MASLD. Virulence factors encoded bacteria ALD, AILD HCC. Novel therapeutic approaches focused phages, pre- postbiotics successfully used preclinical models. Fecal microbiota transplantation has effective attenuating Probiotics are safe hepatitis improve alcohol addiction. Summary gut–liver plays key pathophysiology Understanding help develop precise centered therapies.

Language: Английский

---

Probiotics and the microbiota-gut-brain axis in neurodegeneration: Beneficial effects and mechanistic insights

Life Sciences, Journal Year: 2024, Volume and Issue: 350, P. 122748 - 122748

Published: June 5, 2024

Language: Английский

---

Exploring the role of a novel postbiotic bile acid: Interplay with gut microbiota, modulation of the farnesoid X receptor, and prospects for clinical translation

Microbiological Research, Journal Year: 2024, Volume and Issue: 287, P. 127865 - 127865

Published: Aug. 6, 2024

Language: Английский

---

The Progression of Microbiome Therapeutics for the Management of Gastrointestinal Diseases and Beyond

Gastroenterology, Journal Year: 2024, Volume and Issue: 167(5), P. 885 - 902

Published: May 14, 2024

Language: Английский

---

From dysbiosis to defense: harnessing the gut microbiome in HIV/SIV therapy

Microbiome, Journal Year: 2024, Volume and Issue: 12(1)

Published: June 21, 2024

Abstract Background Although the microbiota has been extensively associated with HIV pathogenesis, majority of studies, particularly those using omics techniques, are largely correlative and serve primarily as a basis for hypothesis generation. Furthermore, most have focused on characterizing taxonomic composition bacterial component, often overlooking other levels microbiome. The intricate mechanisms by which influences immune responses to still poorly understood. Interventional studies gut provide powerful tool test whether we can harness improve health outcomes in people HIV. Results Here, review multifaceted role microbiome HIV/SIV disease progression its potential therapeutic target. We explore complex interplay between microbial dysbiosis systemic inflammation, highlighting microbiome-based therapeutics open new avenues management. These include exploring efficacy probiotics, prebiotics, fecal transplantation, targeted dietary modifications. also address challenges inherent this research area, such difficulty inducing long-lasting alterations complexities study designs, including variations probiotic strains, donor selection FMT, antibiotic conditioning regimens, hurdles translating findings into clinical practice. Finally, speculate future directions rapidly evolving field, emphasizing need more granular understanding microbiome-immune interactions, development personalized therapies, application novel technologies identify agents. Conclusions Our underscores importance target innovative strategies.

Language: Английский

---